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Abstract
Background: Mitochondrial tumor suppressor gene 1 (MTUS1) has been recently identified as a
candidate tumor suppressor gene which resides in a genomic region (8p22) that shows frequent
loss of heterozygosity (LOH) in several tumor types. It has been suggested that multiple gene
promoters and alternative splicing lead to the expression of 5 known MTUS1 transcript variants.
Findings: Here, we characterized the 5' untranslated regions of the different transcript variants.
We also cloned and functionally tested the alternatively utilized gene promoters that contribute to
the production of different MTUS1 transcript variants.
Conclusion: Our results confirmed the early hypothesis that the transcript variants of MTUS1
gene are driven by multiple gene promoters.
Introduction
The MTUS1 gene is located in a region (8p22) that shows
frequent loss of heterozygosity (LOH) in several tumor
types, including oral cancer [1]. Alternative exon utiliza-
tion leads to the production of 5 known transcript vari-
ants (designated as variant 1 to 5) [2]. It has been
suggested that the long form of transcript variants (variant
1, 2, and 3) are driven by a common gene promoter, while
variant 4 and 5 are driven by 2 additional promoters [2].
Variant 5 was the first transcript variant to be cloned inde-
pendently in 2 laboratories, as a gene that is transiently
upregulated during initiation of cell differentiation and
quiescence [3]. It represents an early component of the
growth-inhibiting signaling cascade that interacts with
angiotensin II AT2 receptor [4]. Evidence supporting the
tumor suppressor function of other MTUS1  variants
comes from the study on Xenopus Icis gene, a homolog of
MTUS1  variants 1 and 2, which regulates microtubule
growth and spindle formation prior to anaphase [5].
Here, we refined the genomic structure of the MTUS1 gene
and functionally cloned the alternatively utilized gene
promoters that control the production of these MTUS1
transcript variants. This will enhance our understanding
on the regulation of this candidate tumor suppressor
gene.
Materials and methods
To characterize the 5' untranslated regions (5'-UTR) of the
MTUS1 transcript variants, 5'-RACE assays were carried
out using human brain reference mRNA (Ambion Inc)
and a FirstChoice RLM-RACE kit from Ambion, with
primers specific for various transcript variants (Additional
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file 1). The RACE products were PCR amplified, gel puri-
fied and then sequenced. The sequence results have been
submitted to the GenBank (accession numbers: FJ458439,
FJ458440, FJ458441, FJ472826, and FJ472827 for exon -
1a, -1b, -1c, 5, and 8, respectively).
The gene promoter prediction was carried out using Mat-
Inspector Professional http://genomatrix.de/cgi-bin/
matinspector_prof/mat_fam.pl. The predicted transcrip-
tion elements of the putative promoters were listed in
Additional file 2. To assess the activities of potential gene
promoters that control the productions of MTUS1 tran-
script variants, the following 4 fragments were PCR ampli-
fied using specific primers (Additional file 3) and Human
Reference Genomic DNA (Promega): 1) a 2286 bp frag-
ment (P1) located at the 5' flanking region of the MTUS1
gene; 2) a 773 bp fragment (P1') located at the 5' flanking
region of exon 1; 3) a 529 bp fragment (P2) located at 5'
flanking region of exon 5; and 4) a 733 bp fragment (P3)
located at 5' flanking region of exon 8. The PCR products
were then cloned into the KpnI/XhoI sites of pGL4.10 vec-
tor. After verification by DNA sequencing, the constructs
were transiently transfected into cells using lipofectamine
2000 (Invitrogen). The pGL4.74 vector (Promega) was co-
transfected as internal control for normalization of the
transfection efficiency. After 48 hours, transfected cells
were harvested with ice-cold phosphate-buffered saline,
and dual luciferase assay were performed according to the
manufacturer's protocol (Promega) using a Lumat LB
9507 Luminometer (Berthold Technologies).
Results and Discussion
To characterize the 5'-UTRs of MTUS1 transcription vari-
ants that are controlled by 3 different gene promoters, 5'
RACE assays were performed as described in Materials and
Methods section. The 5'RACE assay designed for the long
forms of MTUS1 transcription variants (variant 1, 2 and 3)
leads to the cloning of the 3 alternatively utilized exons of
91 bp, 169 bp, and 410 bp, respectively (Figure 1B–D).
The 3' portion of the exon -1c (281 bp fragment) was pre-
viously reported in GenBank (NM_001001924). RT-PCR
assays confirm the existence of these non-coding exons
Genomic characterization of the MTUS1 gene Figure 1
Genomic characterization of the MTUS1 gene. Schematic genomic organization of MTUS1 gene is presented in (A). 
Exons are indicated as boxes with corresponding sizes (bp) indicated above. Alternatively utilized gene promoters (P1, P1', P2, 
and P3) are indicated in the appropriated locations. 5'-RACE assays were carried out to characterize the 5' untranslated 
regions (5'-UTRs) corresponding to the long forms of transcription variants (variant 1, 2 and 3), and short forms of transcript 
variants (variant 4 and 5). The sequence alignments of the 5'-UTRs with human chromosome 8 reference sequence 
(NT_030737.9), which locate at exon -1a, -1b, -1c, 5 and 8 of the human MTUS1 gene are presented in (B) to (F), respectively. 
The corresponding GenBank accession numbers for exon -1a, -1b, -1c, 5, and 8 are FJ458439, FJ458440, FJ458441, FJ472826, 
and FJ472827, respectively.
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(data not shown). The 5'RACE assays designed for tran-
scription variant 4 and 5 confirm the existence of these
variants and also refined the 5' untranslated region for
variant 5 (Figure 1E and 1F).
Based on sequence conservation and cap-analysis gene
expression (CAGE) database, 3 gene promoters were pre-
dicted: P1, located at the 5'-flanking region of the gene;
P2, located in intron region 5'-flanking exon 5; and P3,
located in intron region 5'-flanking exon 8. These gene
promoters were supported by sequence conservation
(observed in 4, 9, and 11 of 11 orthologous loci analyzed,
respectively) and CAGE database (supported by 29, 1 and
13 CAGE tages, respectively). The genomic locations of
these putative promoters support the existence of multiple
transcript variants of MTUS1 gene (Figure 1A). Interest-
ingly, consensus sequences of relevant transcription ele-
ments (TATA-box and multiple CAAT sites) were also
observed in a 500 bp fragment located in the intron 5'-
flanking the exon 1 (named P1'), which may potentially
contribute to the expression of the long transcription var-
iants. We cloned these potential gene promoters and
reporter gene assays were performed to evaluate the activ-
ities of these promoters using dual luciferase assay in 4
different cell lines, including a human lung fibroblast cell
line (WI38), an immortalized normal oral keratinocyte
(NOK-16B) and 2 oral tongue SCC cell lines (UM1 and
UM2). As illustrated in Table 1, strong promoter activities
were observed for P3 in all 4 cell lines tested. Promoter
activities were also observed for P1 and P2 in UM1, UM2
and NOK16B, but not in WI38 cells. It is worth noting
that transcript variant 4 (controlled by promoter P2) is a
brain specific variant [2], which may explains the
observed low activity of P2 promoter in our cell lines. No
activity was found for negative control (empty pGL4.10
vector). These results confirmed the early hypothesis that
the transcript variants of MTUS1 gene are driven by mul-
tiple gene promoters. Interestingly, P1', the putative pro-
moter located in the intron region 5'-flanking exon 1 also
exhibited strong promoter activity in all 4 cell lines tested,
which suggests that the long form of transcript variants
(variant 1, 2, and 3) may be regulated by both P1 and P1'
promoters. It is possible that these 2 gene promoters may
serve a cooperated control circuit in vivo to regulate the
expression of this gene. This interesting phenomenon has
been observed in a number of other genes, including gene
for bradykinin B1 receptor [6], and proto-oncogene
MDM2 [7]. Future studies will be needed to fully explore
the potential interaction of P1 and P1' promoters.
In summary, our results refined the genomic structure of
the MTUS1 gene and demonstrated the presence of multi-
ple gene promoters. Characterization of this gene will
now facilitate studies on the physiological and patho-
physiological function and transcriptional regulation of
the MTUS1.
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